{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:13:18Z","timestamp":1791965598972,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008208","name":"Chief Physician Johan Boserup and Lise Boserups Scholarship","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["4285-00212B"],"award-info":[{"award-number":["4285-00212B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase and Ejnar Danielsens Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.atherosclerosis.2026.120772","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:32:44Z","timestamp":1777617164000},"page":"120772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Inflammation may explain part of atherosclerotic cardiovascular disease risk conferred by elevated remnant lipoproteins: a cohort and Mendelian randomization study"],"prefix":"10.1016","volume":"417","author":[{"given":"Benjamin N.","family":"Wadstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders B.","family":"Wulff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper M.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.120772_bib1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MOL.0000000000000867","article-title":"Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease","volume":"34","author":"Wadstrom","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Boren","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040951","article-title":"Targeting inflammatory pathways in cardiovascular disease: the inflammasome, Interleukin-1, Interleukin-6 and beyond","volume":"10","author":"Libby","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib5","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and Anti-Interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib6","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1161\/CIRCULATIONAHA.109.918417","article-title":"Inflammation in peripheral artery disease","volume":"122","author":"Brevetti","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021995","article-title":"Metabolic biomarker discovery for risk of peripheral artery disease compared with coronary artery disease: Lipoprotein and metabolite profiling of 31 657 individuals from 5 prospective cohorts","volume":"10","author":"Tikkanen","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib8","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1093\/eurheartj\/ehab705","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstrom","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib9","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/ATVBAHA.123.320175","article-title":"Remnant cholesterol, not LDL cholesterol, explains peripheral artery disease risk conferred by apoB: a cohort study","volume":"44","author":"Wadstrom","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.gheart.2013.12.008","article-title":"Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010","volume":"9","author":"Sampson","year":"2014","journal-title":"Glob Heart"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib11","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib14","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2017.12.006","article-title":"Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke","volume":"71","author":"Holmes","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib16","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/aje\/kwx016","article-title":"Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -Omic technologies","volume":"186","author":"Wurtz","year":"2017","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib17","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/s41467-019-11311-9","article-title":"A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals","volume":"10","author":"Deelen","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib18","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/nprot.2010.116","article-title":"Data quality control in genetic case-control association studies","volume":"5","author":"Anderson","year":"2010","journal-title":"Nat Protoc"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001779","article-title":"UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age","volume":"12","author":"Sudlow","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish national patient registry: a validation study","volume":"6","author":"Sundboll","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ejvs.2016.12.031","article-title":"Validity of peripheral arterial disease diagnoses in the Danish national patient registry","volume":"53","author":"Lasota","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2020.03.028","article-title":"Reply to: \"methodological issues regarding: \"A third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals\"\"","volume":"302","author":"Wurtz","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib24","article-title":"Genetic regulation of the human plasma proteome in 54,306 UK biobank participants","author":"Sun","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib25","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/oxfordjournals.aje.a116453","article-title":"Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error","volume":"136","author":"Rosner","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/EDE.0b013e318253e418","article-title":"Proportional hazards regression in epidemiologic follow-up studies: an intuitive consideration of primary time scale","volume":"23","author":"Cologne","year":"2012","journal-title":"Epidemiology"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/EDE.0000000000001643","article-title":"Effect measure modification by covariates in mediation: extending regression-based causal mediation analysis","volume":"34","author":"Li","year":"2023","journal-title":"Epidemiology"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010596","article-title":"Strategies to investigate and mitigate collider bias in genetic and Mendelian randomisation studies of disease progression","volume":"19","author":"Mitchell","year":"2023","journal-title":"PLoS Genet"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/clinchem\/hvae222","article-title":"Small remnants versus large triglyceride-rich lipoproteins in risk of atherosclerotic cardiovascular disease","volume":"71","author":"Wadstrom","year":"2025","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.atherosclerosis.2004.10.044","article-title":"Macrophage-derived lipoprotein lipase increases aortic atherosclerosis in cholesterol-fed Tg rabbits","volume":"179","author":"Ichikawa","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.20283","article-title":"Free fatty acids promote hepatic lipotoxicity by stimulating TNF-Alpha expression via a lysosomal pathway","volume":"40","author":"Feldstein","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib33","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1365-2567.2000.00997.x","article-title":"Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes","volume":"100","author":"Mathy","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijcard.2020.03.053","article-title":"Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: a two-sample Mendelian randomization study","volume":"313","author":"Yuan","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102956","article-title":"Effects of tumour necrosis factor on cardiovascular disease and cancer: a two-sample Mendelian randomization study","volume":"59","author":"Yuan","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib37","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib38","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/eurheartj\/ehv759","article-title":"Inflammatory cytokines in atherosclerosis: current therapeutic approaches","volume":"37","author":"Tousoulis","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib39","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/ATVBAHA.116.308834","article-title":"Remnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humans","volume":"37","author":"Bernelot Moens","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103824","article-title":"Mendelian randomization study on the causal effects of tumor necrosis factor inhibition on coronary artery disease and ischemic stroke among the general population","volume":"76","author":"Kang","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib41","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1016\/j.jid.2022.06.015","article-title":"Serum lipids and risk of incident psoriasis: a prospective cohort study from the UK biobank study and Mendelian randomization analysis","volume":"142","author":"Xiao","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/bjd\/ljae089","article-title":"Elevated plasma triglycerides increase the risk of psoriasis: a cohort and Mendelian randomization study","volume":"191","author":"Greve","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib43","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/eji.200838885","article-title":"Negative feedback regulation of IL-32 production by iNOS activation in response to dsRNA or influenza virus infection","volume":"39","author":"Li","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.837588","article-title":"Comparison of the seven Interleukin-32 isoforms' biological activities: IL-32Theta possesses the Most dominant biological activity","volume":"13","author":"Shim","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib45","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.119.315896","article-title":"Metabolic inflammation and insulin resistance in obesity","volume":"126","author":"Wu","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib46","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","article-title":"Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis","volume":"71","author":"Daien","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.05.010","article-title":"Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality","volume":"379","author":"Doi","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib49","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","article-title":"Large-scale plasma proteomics comparisons through genetics and disease associations","volume":"622","author":"Eldjarn","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Smith","year":"2003","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib51","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","article-title":"Mendelian randomization in cardiometabolic disease: challenges in evaluating causality","volume":"14","author":"Holmes","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib52","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the european atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib53","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib54","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib55","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: translate-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib56","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with olezarsen in moderate hypertriglyceridemia","volume":"393","author":"Bergmark","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib57","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib58","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(25)00825-6","article-title":"Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b\/2a clinical studies","volume":"405","author":"Cummings","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib59","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/s41591-025-03830-4","article-title":"Targeting the angiopoietin-like protein 3\/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial","volume":"31","author":"Gaudet","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2026.120772_bib60","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:14:10Z","timestamp":1783145650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026001383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":60,"alternative-id":["S0021915026001383"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120772","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammation may explain part of atherosclerotic cardiovascular disease risk conferred by elevated remnant lipoproteins: a cohort and Mendelian randomization study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120772"}}